Ovulation Induction Agents
Key Points
- Ovulation induction agents stimulate follicular development and ovulation in patients who are anovulatory or undergoing assisted reproductive technology (ART).
- Clomiphene citrate (Clomid): first-line oral SERM; 50 mg daily × 5 days starting on day 5 of cycle; can be titrated to 150 mg daily.
- Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovarian stimulation — monitor for abdominal pain, bloating, nausea, and significant weight gain.
- hCG trigger: used to finalize follicular maturation and trigger ovulation — patients must be warned that hCG causes false-positive home pregnancy tests for at least 14 days after injection.
- Mood swings and depression are common side effects of all ovulation induction medications; emotional support is a core nursing priority.
Mechanism of Action
Ovulation induction medications work by stimulating the hypothalamic-pituitary-ovarian axis at different points to promote follicular development and ovulation:
- Clomiphene citrate (SERM): Blocks estrogen receptors in the pituitary and hypothalamus → interrupts negative feedback → surge in FSH secretion → multiple follicle recruitment and maturation
- Leuprolide (GnRH agonist): Initially stimulates, then suppresses pituitary GnRH receptors → controlled desensitization prevents premature LH surge → allows provider to control cycle timing for ART
- GnRH antagonists: Provide rapid pituitary LH suppression during ovarian stimulation cycles to prevent premature ovulation
- Follitropins (FSH analogs): Exogenous FSH directly stimulates follicular growth → superovulation (development of multiple mature follicles)
- hMG (menotropins): Combined FSH/LH activity supports follicular maturation when broader gonadotropin stimulation is needed
- hCG trigger: Mimics the mid-cycle LH surge → triggers final follicular maturation and ovulation approximately 36 hours after injection
- Letrozole (aromatase inhibitor): Lowers estrogen production, releasing hypothalamic-pituitary feedback inhibition and increasing endogenous gonadotropin secretion
- Metformin: Improves insulin sensitivity in PCOS-associated anovulation and can support return of ovulatory cycles
- Dopamine agonists (bromocriptine, cabergoline): Lower prolactin levels when hyperprolactinemia suppresses ovulation
Drug Classes and Agents
| Drug | Route/Dose | Indication | Key Notes |
|---|---|---|---|
| Clomiphene citrate (Clomid) | 50 mg PO daily × 5 days (day 5 of cycle); can increase to 150 mg | Anovulatory infertility (most often first-line in patients younger than 39 without PCOS) | Black box: visual symptoms; most common initial-line oral agent |
| Letrozole | PO cycle-based dosing per protocol | Ovulation induction, especially in PCOS (often younger than 39) | Aromatase inhibition increases endogenous FSH drive |
| Leuprolide (Lupron Depot) | Subcutaneous injection per protocol | GnRH agonist; suppresses premature LH surge in IVF cycles | Used to control timing of ovulation retrieval |
| GnRH antagonists | Subcutaneous injection per protocol | Prevent premature LH surge during ovarian stimulation | Rapid onset suppression in IVF protocols |
| Follitropins (FSH) | Subcutaneous injection per protocol | Superovulation for IUI or IVF | Requires intensive ultrasound and laboratory monitoring |
| hMG (menotropins) | Subcutaneous or IM injection per protocol | Controlled ovarian stimulation | Provides combined FSH/LH activity |
| hCG (Pregnyl, Ovidrel) | Single IM or subcutaneous injection | Ovulation trigger after follicular maturation confirmed | False-positive pregnancy test for ≥14 days after injection; used with gonadotropin cycles that carry multiple-gestation risk |
| Metformin | PO maintenance dosing per protocol | PCOS with insulin resistance contributing to anovulation | Adjunct to improve ovulatory response in selected patients |
| Bromocriptine/Cabergoline | PO dosing per protocol | Hyperprolactinemia-associated anovulation | Dopamine agonists restore ovulation by reducing prolactin |
Progesterone/Estrogen supplementation: IVF protocols suppress endometrial development; hormonal support may be required to maintain the endometrium during the luteal phase for embryo transfer success.
Adverse Effects
| Drug | Key Adverse Effects |
|---|---|
| Clomiphene citrate | Visual symptoms (blurred vision, photophobia — report immediately; may be irreversible), hot flashes, ovarian enlargement, bloating, nausea/vomiting, breast tenderness, OHSS risk |
| Follitropins (FSH) | OHSS (most serious risk), injection site reactions, multiple gestation |
| Leuprolide | Hypoestrogenic effects (hot flashes, mood changes, bone density loss with long-term use), injection site reactions |
| hCG | OHSS risk, false-positive pregnancy tests |
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS is an exaggerated ovarian response to stimulation characterized by:
- Abdominal pain, bloating, and distension
- Nausea, vomiting, and diarrhea
- Rapid weight gain (>2.2 lb [1 kg] per day)
- Severe: ascites, pleural effusion, hemoconcentration, thromboembolism risk
OHSS risk is highest in patients with PCOS and those with large numbers of recruited follicles. Patients must be instructed to report these symptoms immediately. The provider may cancel the cycle if severe OHSS is developing.
Nursing Assessment
NCLEX Focus
The hCG false-positive pregnancy test is a high-yield counseling point — patients who receive hCG trigger must be told to wait at least 14 days before using a home pregnancy test to avoid a false positive that could cause premature celebration or unwarranted distress.
Pre-treatment:
- Confirm pregnancy test is negative before initiating any ovulation induction cycle
- Assess baseline ovarian ultrasound and hormone levels (FSH, LH, estradiol, AMH)
- Review contraindications for clomiphene: active ovarian cysts, liver disease, abnormal uterine bleeding, pituitary tumors
During treatment:
- Monitor for OHSS symptoms: daily weight, abdominal girth, pain, GI symptoms — escalate rapid weight gain (>1 kg/day) immediately
- For clomiphene: ask about visual symptoms at each contact — blurred vision or scotomata require immediate drug cessation and provider notification
- Track follicular response with serial transvaginal ultrasound and serum estradiol levels
Nursing Interventions
- Emotional support is essential: educate the patient that mood swings, irritability, and depression are common side effects of all ovulation induction drugs — validate these experiences and refer to counseling if needed
- Medication administration teaching: injectable medications (follitropins, leuprolide, hCG) require patient self-injection training; return-demonstration ensures technique safety
- hCG counseling: explicitly state that the hCG trigger will cause a home pregnancy test to read positive for at least 14 days after injection, even if the patient is not pregnant
- Multiple gestation counseling: ovulation induction increases the probability of twins, triplets, or higher-order multiples — this changes the risk profile of the pregnancy and should be discussed before treatment
OHSS in PCOS Patients
Patients with PCOS are at significantly elevated risk for OHSS due to their larger pool of antral follicles. The lowest effective dose of clomiphene should always be used, and FSH dosing in IVF protocols must be carefully titrated. Daily weight monitoring and prompt symptom reporting are essential patient education points.
Related Concepts
- causes-of-infertility — Understanding the underlying cause of infertility guides agent selection and treatment planning.
- functional-reproductive-disorders — PCOS is the most common indication for clomiphene citrate ovulation induction.
- polycystic-ovary-syndrome — Dedicated concept note for PCOS diagnosis, complications, and integrated long-term management.
- conditions-limited-to-pregnancy — Multiple gestation from assisted reproduction raises pregnancy risk profiles significantly.
- fhr-and-uc-intervention-framework — Multiple gestation pregnancies require heightened antepartum surveillance.
- reproductive-system — Hypothalamic-pituitary-ovarian axis physiology underlies all ovulation induction pharmacology.
Self-Check
- A patient receives hCG trigger injection on Monday and calls the clinic Thursday reporting a positive home pregnancy test. She is excited, but the nurse knows ovulation likely just occurred. What is the nurse’s priority counseling point?
- A patient on follitropins calls to report gaining 3 pounds in the past 24 hours and notices her abdomen feels bloated. What should the nurse suspect and what is the priority action?
- Why is clomiphene citrate particularly effective in patients with PCOS who are not ovulating?